CUMYL-BC-HPMEGACLONE-221

Cumyl-BC-HpMeGaClone-221
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 5-({Bicyclo[2.2.1]heptan-2-yl}methyl)-2-(2-phenylpropan-2-yl)-1H,2H,5H-pyrido[4,3-b]indol-1-one;
PubChem CID	163190698;
ChemSpider	115285286;
CompTox Dashboard (EPA)	DTXSID501336924 ;
Chemical and physical data
Formula	C28H30N2O
Molar mass	410.561 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(c1ccccc1)N1C=Cc2n(CC3CC4CCC3C4)c3ccccc3c2C1=O;
	InChI InChI=1S/C28H30N2O/c1-28(2,22-8-4-3-5-9-22)30-15-14-25-26(27(30)31)23-10-6-7-11-24(23)29(25)18-21-17-19-12-13-20(21)16-19/h3-11,14-15,19-21H,12-13,16-18H2,1-2H3; Key:VFBNNQOHBYEVLU-UHFFFAOYSA-N;

Cumyl-BC-HpMeGaClone-221 (Cumyl-NBMeGaClone^[1], Cumyl-BC[2.2.1]HpMeGaClone, SGT-271) is a gamma-carboline derivative which is a synthetic cannabinoid that has been sold as a designer drug.^[2] It was first identified in Germany in September 2020.^[3]

References

↑ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. ISSN 1942-7603. PMID 36346325.
↑ Malaca S, Tini A, Umani Ronchi F (January 2022). "Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights". Acta Bio-Medica. 92 (6): e2021546. doi:10.23750/abm.v92i6.12696. PMC 8823589. PMID 35075053.
↑ European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 978-92-9497-558-4.

[1] Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. ISSN 1942-7603. PMID 36346325.

[2] Malaca S, Tini A, Umani Ronchi F (January 2022). "Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights". Acta Bio-Medica. 92 (6): e2021546. doi:10.23750/abm.v92i6.12696. PMC 8823589. PMID 35075053.

[3] European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 978-92-9497-558-4.

[1]

[2]

[3]

See also

References